APPLICATION STATEMENT

The application of the Clinical Coverage Guideline is subject to the benefit determinations set forth by the Centers for Medicare and Medicaid Services (CMS) National and Local Coverage Determinations and state-specific Medicaid mandates, if any.

DISCLAIMER

The Clinical Coverage Guideline (CCG) is intended to supplement certain standard WellCare benefit plans and aid in administering benefits. Federal and state law, contract language, etc. take precedence over the CCG (e.g., Centers for Medicare and Medicaid Services [CMS] National Coverage Determinations [NCDs], Local Coverage Determinations [LCDs] or other published documents). The terms of a member’s particular Benefit Plan, Evidence of Coverage, Certificate of Coverage, etc., may differ significantly from this Coverage Position. For example, a member’s benefit plan may contain specific exclusions related to the topic addressed in this CCG. Additionally, CCGs relate exclusively to the administration of health benefit plans and are NOT recommendations for treatment, nor should they be used as treatment guidelines. Providers are responsible for the treatment and recommendations provided to the member. The application of the CCG is subject to the benefit determinations set forth by the Centers for Medicare and Medicaid Services (CMS) National and Local Coverage Determinations, and any state-specific Medicaid mandates. Links are current at time of approval by the Medical Policy Committee (MPC) and are subject to change. Lines of business are also subject to change without notice and are noted on www.wellcare.com. Guidelines are also available on the site by selecting the Provider tab, then “Tools” and “Clinical Guidelines”.

BACKGROUND

HP Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. HP Acthar Gel is also indicated for the treatment of exacerbations of multiple sclerosis in adults. HP Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state.¹
POSITION STATEMENT

Applyable To:
☑ Medicaid
☑ Medicare

Exclusions

HP Acthar Gel is unproven and not medically necessary as a first-line therapy in these conditions as treatment with HP Acthar is not well established for the following:

- Rheumatic Disorders: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis
- Collagen Diseases: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)
- For diagnostic testing of adrenocortical function because it has not been shown to be superior to cosyntropin for this purpose.
- For corticosteroid-responsive conditions because it has not been proven to be more effective than corticosteroids for these indications.
- For all other indications including the following (not an all-inclusive list) because its effectiveness for these indications has not been established:
  - Dermatopolymyositis
  - Nephrotic syndrome (including focal segmental glomerulo-sclerosis, idiopathic membranous nephropathy, IgA nephropathy, membrano-proliferative glomerulo-nephritis, and monoclonal diffuse proliferative glomerulo-nephritis)
  - Systemic lupus erythematosus

HP Acthar gel is contraindicated in the following situations:

- For use via intravenous administration.
- In suspected congenital infections in infants.
- Administration of live or live attenuated vaccines in members receiving immunosuppressive doses of HP Acthar gel.
- For individuals with: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, CHF, uncontrolled hypertension, primary adrenocortical insufficiency, and adrenocortical hyperfunction or sensitivity to proteins of porcine origin.

Coverage

Repository corticotropin (HP Acthar® Gel) is considered medically necessary when one of the following is met:

- For the treatment of West syndrome (infantile spasms) in infants and children less than two years of age.

Repository corticotropin injection dosing for infantile spasm is as follows:

  - Initial dose: 75 U/m2 intramuscular (IM) twice daily for 2 weeks.
  - After 2 weeks, dose should be tapered according to the following schedule: 30 U/m2 IM in the morning for 3 days; 15 U/m2 IM in the morning for 3 days; 10 U/m2 IM in the morning for 3 days; and 10 U/m2 IM every other morning for 6 days (3 doses).
  - BSA (m²): \( \sqrt{\frac{\text{weight (kg)} \times \text{height (cm)}}{3600}} \)
  - Additionally, baseline 24 hour EEG displaying hypsarrythmia must be made available.

NOTE: Additional information to support medical necessity review where applicable: The above indication and criteria also apply to medical necessity review.

OR
• For the treatment of multiple sclerosis in adult members 18 years or older:
  o Member is an adult with a corticosteroid-responsive condition, including but not limited to acute exacerbations of multiple sclerosis; **AND**
  o There is denotation of an acute exacerbation lasting at least 24 hours; **AND**
  o Other exacerbation causes such as stress, pain, or infection have been ruled out; **AND**
  o Member has no contraindications to or is not limited by contraindication to or intolerance of glucocorticoid effects; **AND**
  o Immunomodulator use for at least the past 30 days (such as Aubagio, Avonex, Copaxone, Betaseron, Rebif, Gilenya, and Tysabril); **AND**
  o Documented trial & failure of methylprednisolone 160mg daily for one week followed by 64mg every other day for one month; **AND**
  o Other exacerbation causes such as stress, pain, or infection have been ruled out; **AND**
  o Member has no contraindications to or is not limited by contraindication to or intolerance of glucocorticoid effects; **AND**
  o Immunomodulator use for at least the past 30 days (such as Aubagio, Avonex, Copaxone, Betaseron, Rebif, Gilenya, and Tysabril); **AND**
  o There is clear documentation of why all other well-established routes for corticosteroid therapy (for example, oral prednisone and intravenous methylprednisolone) cannot be used.
  o Documentation of taper schedule; **AND**
  o Recommended dosing for the treatment of acute exacerbations of multiple sclerosis in adults is 80 – 120 units injected intramuscularly or subcutaneously daily for 2-3 week.

OR

• *** For the treatment of nephrotic syndrome in adult member 18 years and older:
  o Must have trial and failure or intolerance of at least 1 from the following categories (unless adequate documentation reflects contraindication):
    ▪ Immunosuppressive agents: cyclophosphamide, mycophenolate mofetil, tacrolimus or cyclosporine; **AND/OR**
    ▪ Corticosteroid (Prednisolone, Dexamethasone IV); **AND/OR**
    ▪ Methylprednisolone IM injection.

OR

• *** For the treatment of polymyositis/dermatomyositis in adults 18 years or older:
  o Must have trial and failure or intolerance of at least 1 from each of the following groups (unless adequate documentation reflects contraindication):
    ▪ Corticosteroid (Prednisolone, Dexamethasone IV); **AND**
    ▪ Antimetabolite (azathioprine, methotrexate); **AND**
    ▪ Methylprednisolone IV.

OR

• *** For the treatment of Rheumatoid Arthritis in adult members 18 years and older:
  o Must have trial and failure or intolerance of at least 1 from each of the following groups (unless adequate documentation reflects contraindication):
    ▪ Corticosteroid (Prednisolone, Dexamethasone IV); **AND/OR**
    ▪ Antirhuematic (azathioprine, methotrexate, Humira, Enbrel); **AND/OR**
    ▪ Methylprednisolone IM injection between 40 to 120mg or IV.

OR

• For the treatment of Systemic Lupus Erythematosus in adults 18 years and older:
  o Must have trial and failure or intolerance of at least 1 from each of the following groups (unless adequate documentation reflects contraindication):
    ▪ Corticosteroid (Prednisolone, Dexamethasone IV); **AND/OR**
    ▪ Hydroxychloroquine, Benylsta, azathioprine, cyclosporine, cyclophosphamide, mycophenalate; **AND/OR**
    ▪ Methylprednisolone IV
OR

- For the treatment of Sarcoidosis in adults 18 years and older:
  - Must have trial and failure or intolerance of at least 1 from each of the following groups (unless adequate documentation reflects contraindication)
    - Corticosteroid (IV methylprednisolone, IV dexamethasone, oral prednisone); AND/OR
    - Immunosuppressant (methotrexate, azathioprine); AND/OR

*** These as well as certain collagen diseases, allergic states, ophthalmic diseases, are labeled indications however; HP Acthar is not first-line in these conditions as treatment with HP Acthar is not well established.

CODING

Covered CPT Code
96372  Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

Covered HCPCS Code
J0800  Injection, corticotropin, up to 40 units

Covered ICD-10-CM Diagnosis Codes
D86.0-D86.9  Sarcoidosis
G35  Multiple sclerosis
G40.821 - G40.824  Epileptic spasms [West's syndrome]
L40.54  Psoriatic juvenile arthropathy
M05.00-M05.9  Rheumatoid arthritis with rheumatoid factor
M06.00-M06.09  Rheumatoid arthritis without rheumatoid factor
M06.80-M06.89  Other specified rheumatoid arthritis
M06.9  Rheumatoid arthritis, unspecified
M08.00-M08.09  Unspecified juvenile rheumatoid arthritis
M08.1  Juvenile ankylosing spondylitis
M08.20-M08.29  Juvenile rheumatoid arthritis with systemic onset
M08.3  Juvenile rheumatoid polyarthritis (seronegative)
M08.40-M08.48  Pauciarticular juvenile rheumatoid arthritis
M32.0-M32.9  Systemic lupus erythematosus
M33.00-M33.99  Dermatopolymyositis
M45.0-M45.9  Ankylosing spondylitis
N04.0-N04.9  Nephrotic syndrome

Coding information is provided for informational purposes only. The inclusion or omission of a CPT, HCPCS, or ICD-10 code does not imply member coverage or provider reimbursement. Consult the member's benefits that are in place at time of service to determine coverage (or non-coverage) as well as applicable federal / state laws.

REFERENCES


MEDICAL POLICY COMMITTEE HISTORY AND REVISIONS

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/17/2015</td>
<td>Approved by MPC. New.</td>
</tr>
</tbody>
</table>

Original Effective Date: 10/17/2015 - Revised: 10/6/2016, 8/3/2017, 8/24/2018